Tyra Biosciences, Inc. (NASDAQ:TYRA) Shares Sold by Swiss National Bank

Swiss National Bank decreased its holdings in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) by 19.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 20,700 shares of the company’s stock after selling 5,000 shares during the period. Swiss National Bank’s holdings in Tyra Biosciences were worth $288,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently made changes to their positions in TYRA. Rhumbline Advisers lifted its stake in Tyra Biosciences by 4.1% during the fourth quarter. Rhumbline Advisers now owns 26,202 shares of the company’s stock valued at $364,000 after purchasing an additional 1,027 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Tyra Biosciences by 5.2% in the fourth quarter. Bank of New York Mellon Corp now owns 45,007 shares of the company’s stock worth $626,000 after buying an additional 2,221 shares during the period. US Bancorp DE purchased a new position in shares of Tyra Biosciences in the fourth quarter worth approximately $50,000. Charles Schwab Investment Management Inc. increased its position in shares of Tyra Biosciences by 2.2% in the third quarter. Charles Schwab Investment Management Inc. now owns 173,737 shares of the company’s stock worth $4,085,000 after acquiring an additional 3,792 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in shares of Tyra Biosciences by 1.1% during the third quarter. JPMorgan Chase & Co. now owns 368,647 shares of the company’s stock valued at $8,667,000 after acquiring an additional 3,896 shares during the period. Institutional investors and hedge funds own 84.14% of the company’s stock.

Insider Activity at Tyra Biosciences

In other Tyra Biosciences news, Director Nina S. Kjellson sold 7,779 shares of the stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $16.29, for a total transaction of $126,719.91. Following the transaction, the director now owns 447,857 shares in the company, valued at $7,295,590.53. This trade represents a 1.71 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In the last 90 days, insiders sold 21,998 shares of company stock valued at $344,818. Insiders own 15.40% of the company’s stock.

Tyra Biosciences Price Performance

Shares of Tyra Biosciences stock opened at $9.77 on Monday. The firm has a market cap of $494.39 million, a price-to-earnings ratio of -6.07 and a beta of 1.09. The stock has a 50-day simple moving average of $12.46 and a 200-day simple moving average of $16.30. Tyra Biosciences, Inc. has a 52-week low of $9.49 and a 52-week high of $29.60.

Tyra Biosciences (NASDAQ:TYRA) last posted its earnings results on Thursday, March 27th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.05. As a group, equities research analysts predict that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on TYRA. UBS Group began coverage on shares of Tyra Biosciences in a research report on Tuesday, January 7th. They set a “buy” rating and a $28.00 price objective on the stock. HC Wainwright restated a “buy” rating and set a $30.00 price target on shares of Tyra Biosciences in a report on Tuesday, February 18th. Finally, Wedbush reaffirmed an “outperform” rating and set a $30.00 price objective on shares of Tyra Biosciences in a research report on Friday. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $30.83.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.